Author

C. Sers

h-index 7 View on Semantic Scholar

We have 3 of 26 papers

We haven’t gathered this author’s papers yet. Follow them and we’ll fetch their work.

Not the right person? Other researchers publish under this name.

Aug 2026

Concurrent AXL Inhibition Enhances RAS and ERK Inhibitor Efficacy in KRAS-mutant Pancreatic and Lung Cancer

Combined treatment with the AXL inhibitor bemcentinib together with the RAS(ON) multi-selective tri-complex inhibitor RMC-7977 (RASi) or the ERK-selective inhibitor SCH772984 (ERKi) significantly enhanced growth suppression in human KRAS-mutant pancreatic and lung cancer models.

Yan-Pang Ching, Shruthi Narayanan, Jeffrey A. Klomp et al. · bioRxiv · 0 citations

Open access Jul 2026

Model-guided discovery of MTOR-oriented synergistic drug combinations in colorectal cancer

Colorectal cancer (CRC) exhibits high genetic heterogeneity and frequent resistance to single-agent therapies, highlighting the need for rationally designed drug combinations. We apply a mechanistic modelling framework to prioritise synergistic combinations in 16 CRC cell lines. Simulations of 210 double perturbation...

Viviam Solangeli Bermúdez Paiva, H. Bwanika, M.S. Sigfúsdóttir et al. · npj Systems Biology and Appl... · 0 citations

Open access Jul 2026

Immune evasion in locally advanced mismatch repair-deficient microsatellite instability-high colorectal cancer: Reduced T-cell infiltration and upregulation of epithelial IDO1 expression

The overall immunogenicity and prognostic relevance of immune markers in dMMR/MSI-H CRC depend on tumor stage, and immune profiling could be used for early-stage patient stratification and also suggests the potential benefit of early immunotherapeutic intervention.

Sabina Niyazova, C. Sers, H. Bläker et al. · Oncoimmunology · 0 citations